ストックスクリーナーアプリを入手
0.6957
7.24%
-0.0543
アフターアワーズ：
.71
0.0143
+2.06%
前日終値:
$0.75
開ける：
$0.7194
24時間の取引高:
2.78M
Relative Volume:
1.29
時価総額：
$37.88M
収益：
-
当期純損益:
$-59.69M
株価収益率:
-0.5005
EPS:
-1.39
ネットキャッシュフロー:
$-46.54M
1週間 パフォーマンス:
-20.94%
1か月 パフォーマンス:
-57.58%
6か月 パフォーマンス:
-53.62%
1年 パフォーマンス:
-60.25%
1日の値動き範囲:
$0.6706
$0.7299
1週間の範囲:
$0.6706
$0.88
52週間の値動き範囲:
$0.6706
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
名前
Milestone Pharmaceuticals Inc
セクター
電話
(514) 336-0444
住所
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
MIST を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
0.6957 | 37.88M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-22 | 開始されました | Rodman & Renshaw | Buy |
| 2023-06-20 | ダウングレード | Jefferies | Buy → Hold |
| 2022-04-22 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-29 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-07-24 | アップグレード | Jefferies | Hold → Buy |
| 2020-03-25 | ダウングレード | Jefferies | Buy → Hold |
| 2020-03-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-03-24 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 開始されました | Oppenheimer | Outperform |
| 2019-06-03 | 開始されました | Cowen | Outperform |
| 2019-06-03 | 開始されました | Jefferies | Buy |
| 2019-06-03 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Milestone Pharmaceuticals Inc (MIST) 最新ニュース
MIST stock touches 52-week low at $0.7 amid market challenges - Investing.com India
Milestone Pharmaceuticals (NASDAQ:MIST) Cut to Hold at TD Cowen - Defense World
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst - TradingView
Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen - Yahoo Finance
Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by TD Securities to Hold - Defense World
TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty By Investing.com - Investing.com South Africa
HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating - MarketScreener
Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright - TipRanks
Milestone Pharmaceuticals stock rating cut to hold by TD Cowen - Investing.com India
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Reta - Asianet Newsable
HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World
Milestone CRL affirms integrity of clinical data, says H.C. Wainwright - Yahoo Finance
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - NewsBreak: Local News & Alerts
Sector Update: Health Care Stocks Mixed Friday Afternoon - TradingView
Sector Update: Health Care - TradingView
US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve - Reuters
Milestone Pharmaceuticals: Buy Rating Affirmed Despite CARDAMYST Approval Delay, Strong Market Potential and Robust Financial Position - TipRanks
Milestone Pharmaceuticals (MIST) Receives FDA Response on Etripa - GuruFocus
Milestone flagging following CRL - The Pharma Letter
Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating - Marketscreener.com
Milestone Pharma says FDA declined to approve heart disorder therapy - MSN
Milestone Pharmaceuticals Says FDA Cites Manufacturing Concerns for Etripamil NDA; Shares Fall - Marketscreener.com
FDA Declines Milestone Pharmaceuticals' (MIST) Heart Drug Approval - GuruFocus
Manufacturing issues trip up Milestone's long-awaited FDA landmark - FiercePharma
Milestone Pharma stock in focus after FDA snub (MIST:NASDAQ) - Seeking Alpha
FDA flags issues with Milestone’s new drug application By Investing.com - Investing.com South Africa
FDA Issues Complete Response Letter For Etripamil For PSVT - Marketscreener.com
Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray - TradingView
FDA flags issues with Milestone’s new drug application - Investing.com India
Milestone Pharmaceuticals announces FDA issued CRL for etripamil - TipRanks
US FDA declines to approve Milestone's heart rhythm nasal spray - MarketScreener
FDA Issues Complete Response Letter for Etripamil for PSVT - The Manila Times
US FDA declines to approve Milestone Pharma's heart rhythm nasal spray - Marketscreener.com
Milestone Pharmaceuticals Inc. Announces FDA Issues Complete Response Letter for Etripamil for PSVT - MarketScreener
Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers - Seeking Alpha
HC Wainwright Brokers Decrease Earnings Estimates for MIST - Defense World
Milestone Pharmaceuticals to present clinical data on etripamil - TipRanks
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology - The Manila Times
Breakthrough PSVT Treatment Data: Etripamil Proves Effective for Multiple Episodes - StockTitan
Jones Financial Companies Lllp Raises Stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
HC Wainwright Has Negative Outlook of MIST FY2028 Earnings - Defense World
Milestone Pharmaceuticals sets annual meeting date - Investing.com
Milestone Pharmaceuticals sets annual meeting date By Investing.com - Investing.com UK
PDUFA Date Nearing for New PSVT Drug - Streetwise Reports
Milestone Pharma Expands Sale Agreement, Increases Offering By Investing.com - Investing.com Canada
SEC Form 424B5 filed by Milestone Pharmaceuticals Inc. - Quantisnow
Milestone Pharmaceuticals enters open market sale agreement with Jefferies -March 18, 2025 at 05:51 pm EDT - Marketscreener.com
Milestone Pharma Expands Sale Agreement, Increases Offering - Investing.com India
Milestone Pharmaceuticals (NASDAQ:MIST) Given Buy Rating at HC Wainwright - Defense World
Milestone Pharmaceuticals: Buy Rating Backed by Promising FDA Approval and Market Expansion Prospects - TipRanks
Optimistic Buy Rating for Milestone Pharmaceuticals Driven by Strategic Plans and Financial Strength - TipRanks
Milestone Pharmaceuticals Inc (MIST) 財務データ
収益
当期純利益
現金流量
EPS
10.70%
大文字化:
|
ボリューム (24 時間):